EN | UA
EN | UA

Help Support

Back

Comparison of cardiovascular risk linked with xanthine oxidase inhibitors versus non-users and; febuxostat versus allopurinol users

Comparison of cardiovascular risk linked with xanthine oxidase inhibitors versus non-users and; febuxostat versus allopurinol users Comparison of cardiovascular risk linked with xanthine oxidase inhibitors versus non-users and; febuxostat versus allopurinol users
Comparison of cardiovascular risk linked with xanthine oxidase inhibitors versus non-users and; febuxostat versus allopurinol users Comparison of cardiovascular risk linked with xanthine oxidase inhibitors versus non-users and; febuxostat versus allopurinol users

This retrospective cohort study compared the major adverse cardiovascular events (MACE) and all-cause mortality between xanthine oxidase inhibitors (XOIs) and non-XOI users, and allopurinol and febuxostat users.

See All

Key take away

In this study of total 13,997 gout patients, no benefit of XOI use on risk of major cardiovascular events or all-cause mortality was found; febuxostat had a similar risk of cardiovascular events and all-cause mortality than with allopurinol; concomitant colchicine use decrease all-cause mortality risk  among XOI users and its > 3 days use significantly reduces hospitalizations due to heart failure.

Background

This retrospective cohort study compared the major adverse cardiovascular events (MACE) and all-cause mortality between xanthine oxidase inhibitors (XOIs) and non-XOI users, and allopurinol and febuxostat users.

Method

The propensity scores was used to match XOI users 1:1 to XOI non-users in gout patients under consideration. Febuxostat users were matched 1:3 to allopurinol users. As per colchicine use, the subgroup analyses were directed.

Result

Overall, 3607 (25.8%) were XOI users and 10 390 (74.2%) were XOI non-users out of total 13 997 eligible gout patients. XOI users (n = 3607) showed similar incidence of MACE and all-cause mortality as compared to non-users (n = 3607), Table 1.


Febuxostat (n = 276) users portrayed a similar risk of MACE than with allopurinol users with an inclination towards lower heart failure-related hospitalizations risk, Table 2.


The use of concomitant colchicine decreased the risk for all-cause mortality in XOI users. 

Conclusion

A similar risk profile of MACE and all-cause mortality was observed XOI users and non-users in gout patients. Paitents using febuxostat had similar MACE and all-cause mortality risks nevertheless lower heart failure-related hospitalizations as compared to allopurinol.

Source:

Europe PMC

Article:

Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users.

Authors:

Ju C et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies ua en ru
Try: